# US 2001/0033834 A1 · Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0033834 A1
- Document ID: US20010033834A1
- Status: Published application
- Kind: A1
- Application number: 09/793,173
- Filed: 2001-02-26
- Published: 2001-10-25
- Earliest claimed: 2000-02-26
- Assignees: Artecel, Inc.
- Inventors: William O. Wilkison; Jeffrey Gimble
- Web page: https://patentgrep.com/patent/US20010033834A1

## CPC

- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0618: {Cells of the nervous system}
- C12N 5/067: {Hepatocytes}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2500/30: Organic components
- C12N 2500/44: Thiols, e.g. mercaptoethanol
- C12N 2500/80: from animals
- C12N 2506/1384: from adipose-derived stem cells [ADSC], from adipose stromal stem cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention is in the area of pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof. In particular, the invention includes isolated adipose tissue derived stromal cells that have been induced to express at least one phenotypic characteristic of a neuronal, astroglial, hematopoietic progenitor, or hepatic cell. The invention also includes an isolated adipocyte tissue-derived stromal cell that has been dedifferentiated such that there is an absence of adipocyte phenotypic markers.

## Claims

### Claim 1

An isolated adipose tissue derived stromal cell has been induced to express at least one characteristic of a neuronal cell.

### Claim 2

An isolated adipose tissue derived stromal cell has been induced to express at least one characteristic of an astroglial cell.

### Claim 3

An isolated adipose tissue derived stromal cell has been induced to express at least one characteristic of a hematopoietic progenitor cell.

### Claim 4

An isolated adipose tissue derived stromal cell that has been induced to express at least one characteristic of a hepatic cell.

### Claim 5

An isolated adipose tissue derived stromal cell that has been dedifferentiated such that it has an absence of phenotypic adipose markers.

### Claim 6

An isolated adipose tissue derived stromal cell has been induced to express at least one characteristic of a neurona, astroglial, or hematopoietic progenitor, or hepatic cell in which at least one non-endogenous nucleic acid sequence has been introduced into the cell.

### Claim 7

A method for treating a neurological disorder in a host comprising administering an isolated adipose tissue derived stromal cell that has been induced to express at least one characteristic of a neuronal cell.

### Claim 8

A method for treating a neurological disorder in a host comprising administering an isolated adipose tissue derived stromal cell that has been induced to express at least one characteristic of an astroglial cell.

### Claim 9

A method of improving hepatic function in a patient, comprising administering adipose tissue derived stromal cells induced to express at least one characteristic of a hepatic cell into the hepatic system of a patient.

### Claim 10

A method of improving hematopoietic function in a patient, comprising administering adipose tissue derived stromal cells induced to express at least one characteristic of a hematopoietic progenitor cell into the hematopoietic system of a patient.

### Claim 11

A method for dedifferentiating isolated adipose tissue-derived stromal cells comprising: plating said isolated adipose tissue-derived stromal cells and incubating said cells in medium comprising serum and an embryonic extract.

### Claim 12

A method for dedifferentiating isolated adipose tissue-derived stromal cells, comprising: plating said isolated adipose tissue-derived stromal cells at a density of approximately 1,000 to 500,000 cells/cm2 and incubating said cells in medium comprising i) serum; ii) at least one compound selected from the group consisting of: growth factors, hormones, cytokines and serum factors; and iii) optionally, an embryonic extract.

### Claim 13

A method for inducing an isolated adipose tissue-derived stromal cell to differentiate into a cell of non-mesenchymal lineage, comprising: plating said isolated adipose tissue-derived stromal cells and incubating said cells in medium comprising i) serum; ii) at least one compound selected from the group consisting of: growth factors, hormones, cytokines and serum factors; and iii) an embryonic extract.

### Claim 14 (depends on 7, 8)

The method of claim 7, 8, or 9, wherein said adipose-derived stromal cells are human.

### Claim 15 (depends on 7, 8)

The method of claim 7, 8, or 9, wherein said adipose tissue-derived stromal cells are isolated from omental adipose tissue.

### Claim 16 (depends on 7, 8)

The method of claim 7, 8, or 9, wherein said serum is fetal calf serum.

### Claim 17 (depends on 12)

The method of claim 12, wherein said fetal calf serum is present in said medium at a concentration of about 1 to 30 percent.

### Claim 18 (depends on 13)

The method of claim 13, wherein said fetal calf serum is present in a said medium at a concentration of about 3 to 10 percent.

### Claim 19 (depends on 7, 8)

The method of claim 7, 8, or 9, wherein said medium contains about 1 to 30% embryonic extract of chicken.

### Claim 20 (depends on 15)

The method of claim 15, wherein said concentration of embryonic extract of chicken is about 5 to 15 percent.

### Claim 21 (depends on 7, 8)

The method of claim 7 or 8, wherein said growth factor is selected from the group consisting of: EGF, aFGF, bFGF, NGF, BDNF, bone morphogenetic proteins, ciliary neurotrophic factor, PDGF, HBGF, IGF-I, IGF-II, TGF-α, TGF-β, IL-2, IL-3, IL-7, erythropoietin, c-kit ligand/stem cell factor, and midkine.

### Claim 22 (depends on 7, 8)

The method of claim 7 or 8, wherein said hormone is selected from the group consisting of: growth hormone, insulin and insulin like growth factors.

### Claim 23 (depends on 9)

The method of claim 9, wherein said cell of non-mesenchymal lineage is selected from the group consisting of hematopoietic cells and neuronal cells.

### Claim 24 (depends on 9)

The method of claim 9, further comprising the step of introducing said plated cells into a mammalian subject.

### Claim 25 (depends on 20)

The method of claim 20, wherein said adipose-derived stromal cells are isolated from said subject.

### Claim 26 (depends on 7, 8)

A pleuripotent stem cell produced by the method of claim 7 or 8.

### Claim 27 (depends on 19, 20)

A hematopoietic cell produced according to the method of claim 19 or 20.

### Claim 28 (depends on 19, 20)

A neuronal cell produced according to the method of claim 19 or 20.

### Claim 29

A pleuripotent stem cell generated from isolated adipose tissue-derived stromal cells.

### Claim 30

A method for providing differentiated cells of a non-mesenchymal lineage to a subject, comprising:
a) plating said isolated adipose tissue-derived stromal cells at a density of 1,000 to 500,000 cells/cm2 and incubating said cells in medium comprising serum and an embryonic extract;
b) introducing the cells from step (a) into said subject; wherein cells of the desired type are typically present at corresponding site in a normal subject.

### Claim 31 (depends on 26)

The method of claim 26, wherein said site is CNS tissue and said differentiated cell type is neuronal.

### Claim 32 (depends on 27)

The method of claim 27, wherein said cell type is astroglial.

### Claim 33 (depends on 26)

The method of claim 26, wherein said site is intravenous and said differentiated cell type is hematopoietic.

### Claim 34 (depends on 26)

The method of claim 26, wherein said subject is mammalian.

### Claim 35 (depends on 30)

The method of claim 30, wherein said subject is human.

### Claim 36 (depends on 17)

A method of improving hematopoiesis in a patient, comprising administering cells of claim 17 into said patient.

### Claim 37 (depends on 32)

The method of claim 32, wherein said transplantation is by intravenous infusion.

### Claim 38 (depends on 22)

The cell of claim 22, wherein said cell is transiently or stably transfected with at least one nucleic acid sequence.

### Claim 39 (depends on 22)

The cell of claim 22, wherein said cell is infected with a viral or other vehicle containing at least one desired nucleic acid sequence to be introduced into said cell.

### Claim 40

A dedifferentiated, isolated, adipose tissue derived stromal cell capable of being induced to express at least one characteristic of a non-adipose tissue derived cell.

### Claim 41

An isolated adipose tissue derived stromal cell has been induced to express at least one characteristic of a neuronal cell.

### Claim 42

A composition that includes an adipose tissue derived stromal cell has been induced to express at least one characteristic of an astroglial cell in combination with a pharmaceutically acceptable carrier.

### Claim 43

A composition that includes an adipose tissue derived stromal cell has been induced to express at least one characteristic of a hematopoietic progenitor in combination with a pharmaceutically acceptable carrier.

### Claim 44

A composition that includes an adipose tissue derived stromal cell has been induced to express at least one characteristic of a neuronal, astroglial, hematopoietic, or hepatic derived cell wherein at least one non-endogenous nucleic acid sequence has been introduced into the stromal cell, in combination with a pharmaceutically acceptable carrier.

### Claim 45

An isolated adipose tissue derived stromal cell has been induced to express at least one characteristic of a neuronal cell in a two or three dimensional framework suitable for implantation into a host

### Claim 46

An isolated adipose tissue derived stromal cell has been induced to express at least one characteristic of an astroglial cell in a two or three dimensional framework suitable for implantation into a host.

### Claim 47

An isolated adipose tissue derived stromal cell has been induced to express at least one characteristic of a hematopoietic progenitor cell in a two or three dimensional framework suitable for implantation into a host.

### Claim 48

An isolated adipose tissue derived stromal cell that has been induced to express at least one characteristic of a hepatic cell in a two or three dimensional framework suitable for implantation into a host.
